Does hormonal contraception use increase breast cancer risk for BRCA1 and BRCA2 mutation carriers?

Not Applicable

Completed

• Conditions: Breast cancer; Cancer - Breast

• Registration Number: ACTRN12622000991718
• Lead Sponsor: Kelly-Anne Phillips

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-07-14
• Study Completion: 2022-09-14
• Last Update Posted: 3 October 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 5391

Inclusion Criteria

Pathogenic (class 4 or 5) BRCA1 or BRCA2 germline mutation
Follow-up information available
Born after 1920

Exclusion Criteria

Personal history of cancer at cohort entry (except non-melanoma skin or CIN cervix)
History of bilateral mastectomy at cohort entry

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Breast cancer - diagnosis of invasive breast cancer or Ductal Carcinoma In Situ (DCIS) Note: this is a composite primary outcome. Primary outcome was assessed through pathology reports/records and linkages to cancer registries. [ Any time during follow-up up to 30 years after year of enrolment<br><br>Note: The time point is when the event happens, therefore it is different for every participant.]

Secondary Outcome Measures

Name	Time	Method
il[ Nil]